Key facts
- It has raised $500K; the latest was Seed Round in Mar 2025.
- Notable investors include Y Combinator, Transpose Platform Management, Pioneer Fund, Hustle Fund, Singularity Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Uncommon Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Uncommon Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Uncommon Therapeutics
Developer of gene-based therapeutics designed to treat rare genetic diseases. The company develops therapeutic candidates using gene therapy and molecular approaches, conducts preclinical research and validation studies, and collaborates on development programs, enabling patients with rare diseases and healthcare stakeholders to access targeted treatments addressing underlying genetic causes.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 4
- Website
- uncommontherapeutics.com/
- Ownership
- Privately Held (backing)
Uncommon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Uncommon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Uncommon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.